|
Biodefense Coordination Team (BCT)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP
|
Coordinates implementation of the U.S. National Biodefense Strategy and Presidential Memorandum on the Support for Biodefense towards an integrated, comprehensive approach to manage biodefense activities in support of the broader biodefense enterprise.
|
|
Bioeconomy Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
OD/OSP
|
Discusses and coordinates policy options related to promoting and protecting the bioeconomy.
|
|
Biological Select Agents and Toxins Interagency Policy Committee (BSAT PPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Discusses appropriate oversight of Select Agents and Toxins.
|
|
Biological Select Agents and Toxins sub-Interagency Policy Committee (BSAT Sub-PPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Discusses the appropriate oversight of Select Agents and Toxins; Subcommittee of the Biological Select Agents and Toxins Policy Coordination Committee (BSAT PPC).
|
|
Biomarkers of Exposure and Effect in Agriculture (BEEA)
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) are collaborating to characterize exposure to permethrin and other pesticides by measuring urinary metabolites among participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study.
|
|
Biomarkers of Radiation injury Meeting
|
Meeting/ Workshop
|
ASPR, FDA
|
NIAID
|
Meeting held on June 1st, 2020 provided an overview on biomarkers in general and the state of the research specific to radiation countermeasures and biodosimetry and to understand the developmental challenges unique to their role in these areas. Participants identified gaps, challenges and needs for translational application with regard to special populations. Subject matter experts and researchers in the field of biomarkers, radiobiology, and biodosimetry discussed complexity of identifying and utilizing biomarkers for triage, biodosimetry, and radiation countermeasures.
|
|
Biomarkers, EndpointS, and other Tools (BEST) Resource Glossary
|
Resource Development
|
FDA
|
NCI
|
BEST comprises a glossary that clarifies important definitions of terms used in translational science and medical product development with a focus on terms related to study endpoints and biomarkers. The BEST glossary aims to capture distinctions between biomarkers and clinical assessments and to describe their distinct roles in biomedical research, clinical practice, medical product development, and in the regulation of products by FDA.
|
|
Blood Products Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
CC, NHLBI
|
The Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs of its findings.
|
|
Blood, Organ, and Tissue Safety Committee (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, OS
|
CC, NHLBI
|
The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from the Department of Health and Human Services (HHS) organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The Department of Health and Human Services (HHS) Assistant Secretary for Health serves as the Council Chair, and the Office of the Assistant Secretary of Health (OASH) Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director.
|
|
Blood, Organ, and Tissue Senior Executive Council (BOTSEC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, OS
|
NIAID, CC
|
The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from the Department of Health and Human Services (HHS) organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the Office of the Assistant Secretary for Health (OASH) Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director.
|